Levulan ® : the first approved topical photosensitizer for the treatment of actinic keratosis
- 1 January 2002
- journal article
- review article
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 13 (sup1) , s19-s23
- https://doi.org/10.1080/095466302317414663
Abstract
Actinic keratosis (AK) is a very common skin problem found in patients over 50 years of age, representing an in situ keratinocytic neoplasm that can progress to invasive squamous cell carcinoma of the skin. One Food and Drug Administration-approved treatment for AK of the face and scalp is photodynamic therapy (PDT) with 20% aminolevulinic acid (ALA). This advanced technology has been demonstrated in clinical trials to be effective and well tolerated by patients.Keywords
This publication has 7 references indexed in Scilit:
- Photodynamic therapy of actinic keratoses with topical aminolevulinic acid hydrochloride and fluorescent blue lightJournal of the American Academy of Dermatology, 2001
- Actinic KeratosisAmerican Journal of Clinical Dermatology, 2000
- Topical Aminolevulinic Acid HCl Photodynamic TherapyAmerican Journal of Clinical Dermatology, 2000
- Clinical presentation of actinic keratoses and squamous cell carcinomaJournal of the American Academy of Dermatology, 2000
- The treatment of actinic keratosesJournal of the American Academy of Dermatology, 2000
- Photodynamic Therapy of Actinic Keratosis With Topical 5-Aminolevulinic AcidArchives of Dermatology, 1997
- Actinic keratosesJournal of the American Academy of Dermatology, 1997